Zydus receives final approval from the USFDA for Arsenic Trioxide Injection

Ahmedabad, 14 November, 2018

Zydus Cadila has received the final approval from the USFDA to market Arsenic Trioxide Injection, 10 mg/10 mL (1 mg/mL) single-dose vial (US RLD – TRISENOX®). It will be manufactured at Alidac Pharmaceuticals Ltd., the company's wholly-owned subsidiary located at SEZ, Ahmedabad. Arsenic Trioxide is used to treat a type of leukemia (acute promyelocytic leukemia-APL) when other types of treatment (e.g., chemotherapy) have not worked well or no longer work.

The group now has 228 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.

***